-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The report of the 20th National Congress put forward "promoting the construction of a healthy China and putting the protection of people's health in a strategic position of priority development", pointing out the direction for the development of China's health cause, especially for health security, fertility, aging and the development of traditional Chinese medicine, which are interpreted as follows
.
01 Medical coverage
01 Medical coverage The report of the 20th National Congress pointed out that "improve the social security system, improve the multi-level social security system that covers the whole people, coordinates urban and rural areas, is fair and unified, safe and standardized, and sustainable, and expands the coverage of social insurance"
.
.
This also includes improving the multi-level medical security system
.
The "Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical Security System" issued on March 5, 2020 clarifies: China's medical security system is divided into three levels: basic medical insurance, serious illness insurance and medical assistance, basic medical insurance is the main layer, commercial health insurance is the supplement, and serious illness assistance is the bottom layer, and the three insurance expenditures in 2021 are 2,404.
31 billion yuan, 408.
5 billion yuan and 61.
99 billion yuan respectively, accounting for 83.
6%, 14.
2% and 2.
2% of the total insurance expenditure
。
6%, 14.
2% and 2.
2%.
The so-called commercial health insurance is an insurance that takes the insured's body as the insurance subject and ensures that the insured is compensated for direct expenses or indirect losses in the event of injury caused by illness or accident, including sickness insurance, medical insurance, income protection insurance and long-term care insurance
.
The compensation of commercial health insurance in China increased from 29.
8 billion yuan in 2012 to 408.
5 billion yuan in 2021, an increase of 12.
7 times in 9 years, and the proportion of commercial health insurance compensation in the basic medical insurance expenditure in the same period increased from 3.
7% in 2012 to 17% in 2021, and the protection provided by China's commercial health insurance to patients is also increasing
.
7 times
02 Fertility support
02 Fertility support The report of the 20th National Congress pointed out that "establish a birth support policy system"
.
.
Due to changes in attitudes and higher childcare costs, the number of new births has dropped sharply in recent years, from 17.
86 million in 2016 to 10.
92 million in 2021, a drop of 39%.
92 million in 2021, a drop of 39%.
Specific to the pharmaceutical industry, it is necessary to develop and produce more drugs suitable for children to ensure the healthy growth of
children.
With the support and encouragement for the development of children's drugs, such as the review and approval of new drugs, the acceleration of medical insurance, and the expansion of basic drugs, the scale of China's children's drug market has increased year by year in recent years, from 25.
11 billion yuan in 2007 to 94.
8 billion yuan in 2020, an increase of nearly 3 times
in 13 years.
China has been encouraging the research and development of children's drugs, especially after the drug administration reform in 2015, not only issued a directory to encourage the development of children's drugs, but also gave priority review and other support
to the research and development of eligible children's drugs.
In recent years, the number of clinical trials of children's drugs in China has also been growing, from 16 in 2015 to 102 in late October 2020, in addition to the use of drugs for common diseases in children, the development of drugs for rare diseases in children is also increasing year by year, and the number of clinical trials of drugs for rare diseases in children has also increased from 6 in 2015 to 13 in 2019
.
03 Coping with aging
03 Coping with aging The report of the 20th National Congress pointed out that "implement a national strategy to actively respond to the aging of the population"
.
.
In recent years, China's population structure has undergone tremendous changes, the degree of aging has been increasing, and the proportion of people aged 65 and above in the total population has increased from 9.
4% in 2012 to 14.
2% in 2021, an increase of 4.
8 percentage points in 9 years
.
In 2021, the country's population aged 65 and over has exceeded 200 million (200.
56 million), an increase of 9.
92 million over the previous year.
8 percentage points in 9 years
.
This is an increase of 9.
92 million
over the previous year.
Coping with ageing has risen to the national strategy
.
The elderly are more susceptible to disease than young adults, and the number of outpatient emergency visits in rehabilitation departments (excluding rehabilitation hospitals) in China increased from 21.
19 million in 2010 to 52.
68 million in 2019, an increase of 1.
5 times in 9 years, and decreased slightly in 2020 due to the outbreak of the new crown epidemic, reaching 48.
37 million
.
5 times increase in 9 years
In order to meet the rehabilitation needs of elderly patients, the number of rehabilitation beds in hospitals in China is also increasing rapidly, from 49,926 in 2010 to 246,907 in 2020, an increase of 3 times in 10 years
.
04 Traditional Chinese medicine inheritance and innovation
04 Traditional Chinese medicine inheritance and innovation The report of the 20th National Congress proposed to "promote the inheritance and innovation and development of traditional Chinese medicine"
.
Since 2012, China's traditional Chinese medicine has received unprecedented attention and developed
rapidly.
The Law of the People's Republic of China on Traditional Chinese Medicine promulgated in 2015 emphasizes that the development of traditional Chinese medicine should follow the development law of traditional Chinese medicine, adhere to the combination of inheritance and innovation, maintain and give full play to the characteristics and advantages of traditional Chinese medicine, and use modern science and technology to promote the development of
traditional Chinese medicine theory and practice.
The continuous growth of the TCM inheritance team provides a talent foundation
for TCM inheritance.
China has 90 masters of Chinese medicine, 201 national famous old Chinese medicine doctors, 10 chief scientists of the Qihuang Project, China has trained 140 Qihuang scholars, 149 young Qihuang scholars, and there are 1432 grassroots famous old Chinese medicine experts inheritance studios
in the country.
The innovation of Chinese medicine is getting rid of the shackles of Western medicine and establishing a unique evaluation system
suitable for the characteristics of Chinese medicine.
On December 25, 2020, the State Food and Drug Administration issued the "Implementation Opinions on Promoting the Innovation and Development of Traditional Chinese Medicine", which proposed to establish an evidence system
for the registration and evaluation of traditional Chinese medicines that combines the theory, human experience and clinical trials of traditional Chinese medicine.
In recent years, the enthusiasm of Chinese medicine enterprises to engage in the research and development of traditional Chinese medicines has been increasing, and the number of registration applications for innovative traditional Chinese medicines has been increasing
.
The number of clinical applications (INDs) for innovative Chinese medicine drugs increased from 31 in 2017 to 44 in 2021, reaching 21 in the first half of this year.
The number of NDAs for innovative Chinese medicines has increased from a gap of 8 in 2017 to 19 in 2021
.
The report of the 20th National Congress pointed out the direction for the development of China's pharmaceutical and health undertakings, and pharmaceutical enterprises should also find business opportunities from it, quickly adjust their corporate strategies to the direction guided by the 20th National Congress, make due contributions to the development of China's pharmaceutical and health undertakings, and contribute to the comprehensive promotion of socialist modernization and the great rejuvenation of the Chinese nation
.
Attach:
Attach:
Author: Zhang Nature
